Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens

Publication ,  Conference
Armstrong, AJ; Halabi, S; Tannock, IF; George, DJ; Dewit, R; Eisenberger, M
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2009

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

May 20, 2009

Volume

27

Issue

15

Location

Orlando, FL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

45th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Halabi, S., Tannock, I. F., George, D. J., Dewit, R., & Eisenberger, M. (2009). Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 27). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
Armstrong, A. J., S. Halabi, I. F. Tannock, D. J. George, R. Dewit, and M. Eisenberger. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
Armstrong AJ, Halabi S, Tannock IF, George DJ, Dewit R, Eisenberger M. Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.
Armstrong, A. J., et al. “Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens.” JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15, AMER SOC CLINICAL ONCOLOGY, 2009.
Armstrong AJ, Halabi S, Tannock IF, George DJ, Dewit R, Eisenberger M. Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2009.

Published In

JOURNAL OF CLINICAL ONCOLOGY

ISSN

0732-183X

Publication Date

May 20, 2009

Volume

27

Issue

15

Location

Orlando, FL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

45th Annual Meeting of the American-Society-of-Clinical-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences